{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:32:17Z","timestamp":1793140337589,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013050","name":"Guangdong Provincial Applied Science and Technology Research and Development Program","doi-asserted-by":"publisher","award":["Q202414"],"award-info":[{"award-number":["Q202414"]}],"id":[{"id":"10.13039\/501100013050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["GZC20242097"],"award-info":[{"award-number":["GZC20242097"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82002855"],"award-info":[{"award-number":["82002855"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573152"],"award-info":[{"award-number":["82573152"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.eclinm.2026.104170","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:44:11Z","timestamp":1788176651000},"page":"104170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy and safety of liposomal irinotecan plus nimotuzumab in immune checkpoint inhibitor-refractory recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase II trial"],"prefix":"10.1016","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8873-0061","authenticated-orcid":false,"given":"Shuiqing","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Xin","family":"Bei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nian","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-Yu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linquan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhui","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Qun","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9132-0805","authenticated-orcid":false,"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2026.104170_bib1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2026.104170_bib2","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","article-title":"Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma","volume":"381","author":"Zhang","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2026.104170_bib3","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jama.2022.13997","article-title":"Effect of radiotherapy alone vs radiotherapy with concurrent chemoradiotherapy on survival without disease relapse in patients with low-risk nasopharyngeal carcinoma: a randomized clinical trial","volume":"328","author":"Tang","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2026.104170_bib4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(21)01123-5","article-title":"Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"398","author":"Chen","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2026.104170_bib5","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1002\/cncr.30520","article-title":"Tumor response to neoadjuvant chemotherapy predicts long-term survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: a secondary analysis of a randomized phase 3 clinical trial","volume":"123","author":"Peng","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.eclinm.2026.104170_bib6","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1001\/jama.2023.20181","article-title":"Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial","volume":"330","author":"Mai","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2026.104170_bib7","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","article-title":"Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309)","volume":"41","author":"Yang","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eclinm.2026.104170_bib8","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/S1470-2045(21)00302-8","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2026.104170_bib9","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1038\/s41467-023-40402-x","article-title":"Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent\/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial","volume":"14","author":"Yuan","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.eclinm.2026.104170_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102043","article-title":"Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study","volume":"61","author":"Ding","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.eclinm.2026.104170_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.953","article-title":"892P Camrelizumab plus dalpiciclib in anti-PD-1 refractory recurrent or metastatic nasopharyngeal carcinoma","volume":"35","author":"Ding","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2026.104170_bib12","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1200\/JCO.22.01450","article-title":"Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma: an open-label, single-arm, phase II study","volume":"41","author":"Ding","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.104170_bib13","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.medj.2022.07.009","article-title":"Gemcitabine combined with apatinib and toripalimab in recurrent or metastatic nasopharyngeal carcinoma","volume":"3","author":"You","year":"2022","journal-title":"Med"},{"key":"10.1016\/j.eclinm.2026.104170_bib14","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12916-023-02790-1","article-title":"The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and\/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial","volume":"21","author":"Tang","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.eclinm.2026.104170_bib15","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12916-025-03985-4","article-title":"Efficacy and safety of cadonilimab (PD-1\/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial","volume":"23","author":"Jiang","year":"2025","journal-title":"BMC Med"},{"key":"10.1016\/j.eclinm.2026.104170_bib16","doi-asserted-by":"crossref","first-page":"243","DOI":"10.14740\/wjon610w","article-title":"Prognostic value of molecular markers and implication for molecular targeted therapies in nasopharyngeal carcinoma: an update in an era of new targeted molecules development","volume":"6","author":"Liu","year":"2015","journal-title":"World J Oncol"},{"key":"10.1016\/j.eclinm.2026.104170_bib17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00005537-200401000-00029","article-title":"Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynx","volume":"114","author":"Leong","year":"2004","journal-title":"Laryngoscope"},{"key":"10.1016\/j.eclinm.2026.104170_bib18","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2147\/OTT.S77283","article-title":"Nimotuzumab enhances radiation sensitivity of NSCLC H292 cells in vitro by blocking epidermal growth factor receptor nuclear translocation and inhibiting radiation-induced DNA damage repair","volume":"8","author":"Teng","year":"2015","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.eclinm.2026.104170_bib19","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1111\/j.1745-7254.2007.00681.x","article-title":"Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives","volume":"28","author":"Zhu","year":"2007","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.eclinm.2026.104170_bib20","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/annonc\/mdz020","article-title":"Anti-epidermal growth factor receptor (EGFR) monoclonal antibody combined with cisplatin and 5-fluorouracil in patients with metastatic nasopharyngeal carcinoma after radical radiotherapy: a multicentre, open-label, phase II clinical trial","volume":"30","author":"Zhao","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eclinm.2026.104170_bib21","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s12916-025-04103-0","article-title":"Nimotuzumab combined with docetaxel and cisplatin as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma: a multicenter, phase 2 trial","volume":"23","author":"Zou","year":"2025","journal-title":"BMC Med"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104170_bib22","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s12328-025-02139-6","article-title":"Long-term survival with complete remission after irinotecan plus cisplatin therapy for metachronous liver metastasis from a gastric mixed neuroendocrine-non-neuroendocrine neoplasm: a case report","volume":"18","author":"Yasuda","year":"2025","journal-title":"Clin J Gastroenterol"},{"key":"10.1016\/j.eclinm.2026.104170_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115424","article-title":"Phase 1\/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment","volume":"222","author":"Imaoka","year":"2025","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.eclinm.2026.104170_bib24","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jhep.2025.03.013","article-title":"Liposomal irinotecan for previously treated patients with biliary tract cancer: a pooled analysis of NIFTY and NALIRICC trials","volume":"83","author":"Yoo","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.eclinm.2026.104170_bib25","first-page":"332","article-title":"[Apoptosis of nasopharyngeal carcinoma cells induced by topoisomerase I inhibitor]","volume":"32","author":"Zhang","year":"1997","journal-title":"Zhonghua Er Bi Yan Hou Ke Za Zhi"},{"key":"10.1016\/j.eclinm.2026.104170_bib26","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/cncr.20802","article-title":"Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma","volume":"103","author":"Poon","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.eclinm.2026.104170_bib27","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","article-title":"BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study","volume":"25","author":"Ma","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eclinm.2026.104170_bib28","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/s41591-025-03600-2","article-title":"A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1\/1b trial","volume":"31","author":"Ma","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2026.104170_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41467-024-55090-4","article-title":"Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after \u2265 2 prior lines of chemotherapy: a phase Ib study","volume":"16","author":"Fan","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.eclinm.2026.104170_bib30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11095-017-2278-0","article-title":"Liposomal Irinotecan accumulates in metastatic lesions, crosses the blood-tumor barrier (BTB), and prolongs survival in an experimental model of brain metastases of triple negative breast cancer","volume":"35","author":"Mohammad","year":"2018","journal-title":"Pharm Res"},{"key":"10.1016\/j.eclinm.2026.104170_bib31","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2026.104170_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2024.106723","article-title":"Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): a phase II multicenter study","volume":"151","author":"Chen","year":"2024","journal-title":"Oral Oncol"},{"key":"10.1016\/j.eclinm.2026.104170_bib33","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-023-01445-1","article-title":"First-in-human phase I\/Ib study of QL1706 (PSB205), a bifunctional PD1\/CTLA4 dual blocker, in patients with advanced solid tumors","volume":"16","author":"Zhao","year":"2023","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.eclinm.2026.104170_bib34","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13045-025-01666-6","article-title":"Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib\/II trial","volume":"18","author":"Chen","year":"2025","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.eclinm.2026.104170_bib35","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1200\/JCO.2022.40.16_suppl.6024","article-title":"A phase Ib study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-\u03b2, in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC)","volume":"40","author":"Yang","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.104170_bib36","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-26-0347","article-title":"TQB2618 plus penpulimab, alone or in combination with chemotherapy, for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, two-cohort, phase 2 trial","author":"Xu","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eclinm.2026.104170_bib37","first-page":"370","article-title":"EGFR blockade reverses cisplatin resistance in human epithelial ovarian cancer cells","volume":"24","author":"Poursheikhani","year":"2020","journal-title":"Iran Biomed J"},{"key":"10.1016\/j.eclinm.2026.104170_bib38","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2415389122","article-title":"EGFR-induced lncRNA TRIDENT promotes drug resistance in non-small cell lung cancer via phospho-TRIM28-mediated DNA damage repair","volume":"122","author":"Saxena","year":"2025","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eclinm.2026.104170_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23126489","article-title":"EGFR-Mutated non-small cell lung cancer and resistance to immunotherapy: role of the tumor microenvironment","volume":"23","author":"Madeddu","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.eclinm.2026.104170_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2026.101029","article-title":"Becotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase IIa trial","volume":"7","author":"Han","year":"2026","journal-title":"Med"},{"key":"10.1016\/j.eclinm.2026.104170_bib41","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.eclinm.2026.104170_bib42","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1008866","article-title":"Trial Watch: immunogenic cell death inducers for anticancer chemotherapy","volume":"4","author":"Pol","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.eclinm.2026.104170_bib43","doi-asserted-by":"crossref","first-page":"14531","DOI":"10.1021\/acs.nanolett.4c03678","article-title":"Small-Molecule therapeutics achieve multiple mechanism-mediated sensitizations of colorectal cancer to immune checkpoint blockade via neutrophil micropharmacies","volume":"24","author":"Li","year":"2024","journal-title":"Nano Lett"},{"key":"10.1016\/j.eclinm.2026.104170_bib44","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.23.02110","article-title":"RESILIENT part 2: a randomized, open-label phase III study of liposomal Irinotecan versus topotecan in adults with relapsed small cell lung cancer","volume":"42","author":"Spigel","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eclinm.2026.104170_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104386","article-title":"Safety and efficacy of liposomal irinotecan as the second-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis","volume":"201","author":"Chen","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.eclinm.2026.104170_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1250136","article-title":"Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-world study","volume":"13","author":"Gupta","year":"2023","journal-title":"Front Oncol"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026004232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537026004232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:32:32Z","timestamp":1793136752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537026004232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":46,"alternative-id":["S2589537026004232"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104170","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of liposomal irinotecan plus nimotuzumab in immune checkpoint inhibitor-refractory recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase II trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2026.104170","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104170"}}